Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | XX9N4 | IM |
administered a dose of Priorix intramuscularly instead of subcutaneously; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 61-year-old male patient who received MMR (Priorix) (batch number XX9N4, expiry date 01-JUN-2026) for prophylaxis. On 21-MAR-2025, the patient received Priorix (intramuscular). On 21-MAR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: administered a dose of Priorix intramuscularly instead of subcutaneously). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-MAR-2025 Pharmacist called to report that on 21st March 2025 has administered a dose of Priorix intramuscularly instead of subcutaneously, which led to Subcutaneous injection formulation administered by other route.